FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age|
Novartis International AG /
FDA expands age indication for Menveo®, first and only quadrivalent
meningococcal vaccine for infants as young as 2 months of age
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Meningococcal disease is a leading cause of bacterial meningitis, a rapidly
progressing disease that can lead to death in otherwise healthy
* The highest rates of meningococcal disease in the US occur in infants;
babies younger than 7 months old are the most vulnerable
* Menveo now offers the most comprehensive age range coverage in the US
against meningococcal disease caused by serogroups A,C, Y and W-135
Basel, August 1, 2013 - Novartis announced today that the US Food and Drug
Administration (FDA) approved Menveo(®) (Meningococcal Group A, C, W-135 and Y
conjugate vaccine) for the prevention of meningococcal disease caused by four
strains of the bacterium Neisseria meningitidis (N. meningitidis) in infants and
toddlers from 2 months of age. With this expanded indication, pediatricians
in the US can now offer a single vaccine for the protection of infants, children
and adolescents against four of the five most common serogroups that cause
"Each year, more children in the US die or are left with permanent disability
from meningococcal disease than from two other diseases combined that we
routinely vaccinate infants against - rotavirus and varicella," said Dr. Steve
Black, Center for Global Health, University of Cincinnati Children's Hospital.
"With the expanded indication for this MCV4 vaccine, we now have the opportunity
to help protect our infants against four strains of meningococcal disease
earlier, when they are most vulnerable."
Infants younger than 7 months old are the most vulnerable age group to
meningococcal disease in the US. In their first year of life, infants are more
than seven times more likely to contract the disease than 14 to 24 year olds.
Of the infants who contract the disease, more than 10 percent will die from it
and of those who do survive, approximately one in every five will suffer
permanent, devastating side effects, including amputations, hearing loss,
paralysis and brain damage,.
"Despite recommendations for routine immunization of adolescents, college
students living in dormitories and certain infants in the US, meningococcal
disease continues to kill and maim," said Andrin Oswald, Head of Novartis
Vaccines and Diagnostics. "With this approval for the expanded use of Menveo, we
hope that health authorities will deploy this vaccine to further reduce the
burden of this devastating disease in the US."
This FDA approval was based on data from three randomized multicenter studies
involving more than 8,700 infants, conducted in Australia, Canada, Latin
America, Taiwan and the US. The studies demonstrated that Menveo generated a
robust protective immune response and was generally well tolerated when
administered with other routine pediatric vaccines.
Menveo is a quadrivalent conjugate vaccine for use to protect against invasive
disease caused by four groups of the bacterium Neisseria meningitidis (A, C, Y
and W-135). As of July 2013, Menveo is registered in more than 50 countries
for active immunization to prevent invasive meningococcal disease caused by
Neisseria meningitidis serogroups A, C, W-135 and Y. Studies are ongoing in
infants, toddlers, adolescents and adults.
Menveo has been available for use in adolescents and adults (11 to 55 years of
age) since February 2010 and in children (2 to 10 years of age) since January
For more information about Menveo, visit www.menveo.com.
Important Safety Information
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of Menveo,
any component of this vaccine, or any other CRM(197), diphtheria toxoid or
meningococcal-containing vaccine is a contraindication to administration of
Menveo. Appropriate medical treatment must be available should an acute allergic
reaction, including an anaphylactic reaction, occur following administration of
Syncope, sometimes resulting in falling injury associated with seizure-like
movements has been reported following vaccination with Menveo. Vaccinees should
be observed for at least 15 minutes after vaccine administration to prevent and
manage syncopal reactions.
Safety and effectiveness of Menveo have not been evaluated in immunocompromised
persons. If Menveo is administered to immunocompromised persons, including those
receiving immunosuppressive therapy, the expected immune response may not be
Guillain-Barré Syndrome (GBS) has been reported in temporal relationship
following administration of another US-licensed meningococcal quadrivalent
polysaccharide conjugate vaccine. The decision to administer Menveo to subjects
with a known history of GBS should take into account the potential benefits and
Apnea following intramuscular vaccination has been observed in some infants born
prematurely. The decision about when to administer an intramuscular vaccine,
including Menveo, to an infant born prematurely should be based on consideration
of the individual infant's medical status, and the potential benefits and
possible risks of vaccination.
In clinical trials, common solicited adverse reactions with Menveo among
children initiating vaccination at 2 months of age and receiving the four-dose
series were tenderness and erythema at injection site, irritability, sleepiness,
persistent crying, change in eating habits, vomiting and diarrhea. Common
solicited adverse reactions among children initiating vaccination at 7 months
through 23 months of age and receiving the two-dose series were tenderness and
erythema at injection site, irritability, sleepiness, persistent crying, change
in eating habits and diarrhea. Common solicited adverse reactions among children
2 years through 10 years of age were injection site pain, erythema,
irritability, induration, sleepiness, malaise, and headache. Common solicited
adverse reactions among adolescents and adults were pain at the injection site,
headache, myalgia, malaise and nausea. Some events were severe. Safety has not
been established in pregnant women. Vaccination with Menveo may not protect all
Before administering Menveo, please see full Prescribing Information.
The foregoing release contains forward-looking statements that can be identified
by terminology such as "can," "opportunity," "hope," "will," "potential," "may,"
or similar expressions, or by express or implied discussions regarding potential
new indications or labeling for Menveo or regarding potential future revenues
from Menveo. You should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results with Menveo to be materially different
from any future results, performance or achievements expressed or implied by
such statements. There can be no guarantee that Menveo will be approved for any
additional indications or labeling in any market, or at any particular time. Nor
can there be any guarantee that Menveo will achieve any particular levels of
revenue in the future. In particular, management's expectations regarding Menveo
could be affected by, among other things, unexpected regulatory actions or
delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; unexpected manufacturing issues; the company's ability
to obtain or maintain patent or other proprietary intellectual property
protection; the impact that the foregoing factors could have on the values
attributed to the Novartis Group's assets and liabilities as recorded in the
Group's consolidated balance sheet, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Novartis is
providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 131,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at
 Menveo Prescribing Information. Revised August 13, 2013. To be confirmed.
 Centers for Disease Control and Prevention. Vaccine Information Statements
(VIS). Meningococcal VIS. October 2011 Update. Available at:
http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening.html. Accessed July
 Poland, GA. Prevention of Meningococcal Disease: Current Use of
Polysaccharide and Conjugate Vaccines. Clinical Infectious Diseases 2010:50
 Cohn, A. et al. Changes in Neisseria meningitides Disease Epidemiology in
the United States, 1998-2007: Implications for Prevention of Meningococcal
Disease. Clinical Infectious Diseases 2010:50.
 Centers for Disease Control and Prevention. Meningococcal Disease:
Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book:
Course Textbook). 12 Edition, 2nd Printing. May 2012 update. Available at:
http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed: July 2013.
 World Health Organization. Meningococcal meningitis. Fact sheet #141.
November 2012. Available at:
http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed July 2013.
 Novartis Press Release. FDA requests additional data on Novartis
quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in
infants and toddlers. Available at: http://www.novartis.com/newsroom/media-
releases/en/2012/1584870.shtml. Accessed July 2013.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Liz Power
Novartis Global Media Relations Novartis Division Communications
+41 61 324 7999 (direct) +1 617 871 7985 (direct)
+41 79 593 4202 (mobile) +1 617 583 3015 (mobile)
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188 Edwin Valeriano +1 212 830 2456
e-mail: firstname.lastname@example.org e-mail:
Media release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
durchschnittliche Punktzahl: 1.8|